A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
A phase 1/2 trial of Amivantamab, Pembrolizumab and Carboplatin in head and neck squamous cell carcinoma, run by Janssen Research & Development, LLC, now recruiting.
Overview
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer is a phase 1/2 interventional study registered as NCT06385080 by Janssen Research & Development, LLC, with 287 participants planned, started 2024-04-22 and due to reach its primary completion in 2032-12-27. Interventions recorded: Amivantamab, Pembrolizumab, Paclitaxel and Carboplatin.
Similar pages
not linked directly; found by shared links- TrialA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Shares Amivantamab, Johnson & Johnson, Carboplatin, Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Shares Amivantamab, Johnson & Johnson, Carboplatin and the tag pipeline.
- TrialA Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
Shares Amivantamab, Johnson & Johnson, Carboplatin and the tag pipeline.
- TrialA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Shares Amivantamab, Johnson & Johnson, Carboplatin and the tag pipeline.
- TrialA Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Shares Amivantamab, Johnson & Johnson, Carboplatin and the tag pipeline.
- TrialA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Shares Amivantamab, Johnson & Johnson, Carboplatin and the tag pipeline.
- TrialEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Shares Amivantamab, Johnson & Johnson and the tag pipeline.
- TrialA Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Shares Amivantamab, Johnson & Johnson and the tag pipeline.